Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.
Quick Facts
What This Study Found
Amylin receptor agonists like cagrilintide and dual-action compounds show strong potential for obesity treatment, especially when combined with GLP-1 receptor agonists, by targeting both homeostatic and reward-driven eating pathways.
Key Numbers
Not specified in abstract. References pramlintide, cagrilintide, KBP-series DACRAs, ZP8396, and amycretin.
How They Did This
Narrative review of preclinical and clinical evidence on amylin receptor agonists for obesity. Covers molecular pharmacology, clinical development, genetic variants, and combination strategies.
Why This Research Matters
GLP-1 drugs alone produce meaningful but limited weight loss. Adding amylin-based drugs could push results further by targeting a different hormone system that controls hunger, stomach emptying, and food reward.
What This Study Doesn't Tell Us
Narrative review without systematic search or meta-analysis. Most amylin-based agents are still investigational. Long-term efficacy and safety data are limited. Disease-modifying effects beyond weight loss remain unproven.
Trust & Context
- Original Title:
- Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.
- Published In:
- Vascular pharmacology, 162, 107563 (2025)
- Authors:
- Rejili, Mokhtar, Hussain, Md Sadique, Khan, Yumna, Haouala, Faouzi, Ganesan, Subbulakshmi, Sahoo, Samir, Pal, Amrita, Arora, Vimal
- Database ID:
- RPEP-13237
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-13237APA
Rejili, Mokhtar; Hussain, Md Sadique; Khan, Yumna; Haouala, Faouzi; Ganesan, Subbulakshmi; Sahoo, Samir; Pal, Amrita; Arora, Vimal. (2025). Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.. Vascular pharmacology, 162, 107563. https://doi.org/10.1016/j.vph.2025.107563
MLA
Rejili, Mokhtar, et al. "Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.." Vascular pharmacology, 2025. https://doi.org/10.1016/j.vph.2025.107563
RethinkPeptides
RethinkPeptides Research Database. "Amylin receptors as therapeutic targets in obesity: Emerging..." RPEP-13237. Retrieved from https://rethinkpeptides.com/research/rejili-2025-amylin-receptors-as-therapeutic
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.